WO2026055398 - STABLE LETERMOVIR LIQUID FORMULATIONS
National phase entry is expected:
Publication Number
WO/2026/055398
Publication Date
12.03.2026
International Application No.
PCT/US2025/044970
International Filing Date
04.09.2025
Title **
[English]
STABLE LETERMOVIR LIQUID FORMULATIONS
[French]
FORMULATIONS LIQUIDES DE LÉTERMOVIR STABLES
Applicants **
PATEL, Sandipkumar
Inventors
PATEL, Sandipkumar
Priority Data
63/690,681
04.09.2024
US
63/703,627
04.10.2024
US
63/730,141
10.12.2024
US
63/769,759
11.03.2025
US
63/830,459
26.06.2025
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
|
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Natural Person
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3228 | |
| EPO | Filing, Examination, Granting | 16101 | |
| Japan | Filing, Examination, Granting | 2801 | |
| South Korea | Filing, Examination, Granting | 3465 | |
| USA | Filing, Examination, Granting | 11130 |
Total:
36,725
Contact Us
Abstract[English]
Liquid pharmaceutical formulation of letermovir or pharmaceutically acceptable salt thereof is provided. The liquid formulation of letermovir comprises letermovir, a solubilizer or suspending agent, and one or more optional pharmaceutically acceptable excipients, wherein the formulation is suitable for oral or injectable route of administration. The method of preparing the liquid letermovir formulation and the use of such formulation for the treatment of diseases treatable by letermovir is described.[French]
L'invention concerne une formulation pharmaceutique liquide de létermovir ou d'un sel pharmaceutiquement acceptable associée. La formulation liquide de létermovir comprend du létermovir, un agent de solubilisation ou un agent de suspension, et un ou plusieurs excipients pharmaceutiquement acceptables facultatifs, la formulation se prêtant à une voie d'administration orale ou injectable. L'invention concerne le procédé de préparation de la formulation de létermovir liquide et l'utilisation d'une telle formulation pour le traitement de maladies pouvant être traitées par létermovir.